A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS ...

Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

A triple-drug regimen combining two immunotherapy agents with radiation before surgery appears to activate immune defenses ...

A DR5-mediated apoptotic strategy combined with irinotecan/temozolomide achieved a 64.5% ORR and 87.1% DCR in response-evaluable relapsed/refractory Ewing sarcoma. Activity was observed even in ...

The MarketWatch News Department was not involved in the creation of this content.-- Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equiv ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On ...

First Patient Dosed for lead oncology program: ST-01156, a novel oral RBM39 degrader, initiated Phase 1a clinical trials in January 2026 following IND clearance in both the U.S. and China Financing ...

Sun Pharmaceutical Industries Limited has shared clinical updates on Fibromun and Nidlegy, with key studies failing to meet primary endpoints while further trials and regulatory ...

Maya and Angus both survived childhood cancer, but the treatments that saved their lives left them with chronic health issues ...

Michael Bishop, who has died aged 90, shared the 1989 Nobel Prize in Physiology or Medicine with Harold Varmus for proving ...

Inhibrx Biosciences is a high-risk, catalyst-driven biotech, with valuation hinging on the clinical success of ozekibart and ...

INDIANAPOLIS — In an encouraging 2026 Annual Report, the American Cancer Society says seven in ten people now survive their ...